Greenleaf Trust raised its stake in ProNAi Therapeutics Inc. (NASDAQ:DNAI) by 7.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 207,450 shares of the company’s stock after buying an additional 14,956 shares during the period. Greenleaf Trust’s holdings in ProNAi Therapeutics were worth $413,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vivo Capital LLC purchased a new position in ProNAi Therapeutics during the first quarter worth approximately $16,434,000. Deerfield Management Co. increased its position in ProNAi Therapeutics by 67.6% in the first quarter. Deerfield Management Co. now owns 3,001,302 shares of the company’s stock worth $20,229,000 after buying an additional 1,210,047 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in ProNAi Therapeutics by 16.2% in the first quarter. Renaissance Technologies LLC now owns 45,300 shares of the company’s stock worth $305,000 after buying an additional 6,300 shares in the last quarter. Institutional investors and hedge funds own 35.25% of the company’s stock.

Institutional Ownership by Quarter for ProNAi Therapeutics (NASDAQ:DNAI)

ProNAi Therapeutics Inc. (NASDAQ:DNAI) remained flat at $1.86 during mid-day trading on Thursday. 249,052 shares of the company’s stock were exchanged. ProNAi Therapeutics Inc. has a 1-year low of $1.77 and a 1-year high of $20.85. The company’s market cap is $56.40 million. The firm’s 50 day moving average is $1.87 and its 200 day moving average is $3.51.

ProNAi Therapeutics (NASDAQ:DNAI) last posted its quarterly earnings data on Friday, August 12th. The company reported ($0.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.05. On average, analysts forecast that ProNAi Therapeutics Inc. will post ($1.32) EPS for the current year.

Separately, Zacks Investment Research lowered ProNAi Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 15th.

ProNAi Therapeutics Company Profile

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

5 Day Chart for NASDAQ:DNAI

Want to see what other hedge funds are holding DNAI? Visit to get the latest 13F filings and insider trades for ProNAi Therapeutics Inc. (NASDAQ:DNAI).

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with's FREE daily email newsletter.